Technology Prognosis

tracking technologies before you have to make a decision


June 10, 2019

Brolucizumab is a humanized single-chain antibody fragment designed to inhibit activation of vascular endothelial growth factor (VEGF) receptors. Inhibition of the VEGF pathway is believed to impede the growth of neovascular lesions, resolve retinal edema, and improve vision in patients with neovascular age-related macular degeneration.